Arcturus Therapeutics (ARCT) Competitors

Mesoblast (NASDAQ:MESO) and Arcturus Therapeutics (NASDAQ:ARCT) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Do insiders & institutionals hold more shares of MESO or ARCT?

1.4% of Mesoblast shares are owned by institutional investors. Comparatively, 94.5% of Arcturus Therapeutics shares are owned by institutional investors. 18.8% of Mesoblast shares are owned by insiders. Comparatively, 16.6% of Arcturus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Does the media refer more to MESO or ARCT?

In the previous week, Mesoblast had 8 more articles in the media than Arcturus Therapeutics. MarketBeat recorded 10 mentions for Mesoblast and 2 mentions for Arcturus Therapeutics. Mesoblast's average media sentiment score of 0.27 beat Arcturus Therapeutics' score of 0.00 indicating that Mesoblast is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mesoblast	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcturus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is MESO or ARCT more profitable?

Mesoblast has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -47.47%. Mesoblast's return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mesoblast	N/A	N/A	N/A
Arcturus Therapeutics	-47.47%	-27.41%	-19.01%

Do analysts rate MESO or ARCT?

Mesoblast currently has a consensus price target of $18.00, suggesting a potential upside of 20.24%. Arcturus Therapeutics has a consensus price target of $54.00, suggesting a potential upside of 293.59%. Given Arcturus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Arcturus Therapeutics is more favorable than Mesoblast.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mesoblast	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Arcturus Therapeutics	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	3.11

Which has more risk & volatility, MESO or ARCT?

Mesoblast has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. Comparatively, Arcturus Therapeutics has a beta of 2.27, meaning that its stock price is 127% more volatile than the S&P 500.

Which has higher earnings & valuation, MESO or ARCT?

Arcturus Therapeutics has higher revenue and earnings than Mesoblast.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mesoblast	$5.90M	324.21	-$87.96M	N/A	N/A
Arcturus Therapeutics	$131.27M	2.83	-$80.94M	-$2.53	-5.42

Summary

Mesoblast beats Arcturus Therapeutics on 8 of the 14 factors compared between the two stocks.